Current status and outlook of research in treatment of unexplained recurrent spontaneous abortion

胡欧婵,黄仲英
DOI: https://doi.org/10.3877/cma.j.issn.1673-5250.2023.01.003
2023-01-01
Abstract:Recurrent spontaneous abortion (RSA) is typically defined as two or more consecutive spontaneous miscarriage with global incidence of 1%-5%. Among them, about 50% cases were with unknown causes, namely unexplained recurrent spontaneous abortion (URSA). Studies showed that URSA may be related to the maternal-fetal immune imbalance while the exact etiology and pathogenesis underlying URSA remains unclear. At present, it is still lack of recognized effective treatments for URSA. Various treatments such as lymphocyte immunotherapy (LIT), intravenous immunoglobulin (IVIG), immunosuppressant, immunomodulator, progesterone and anticoagulant therapy have been tried in URSA women although efficacy and safety of certain treatments are controversial. Here we summarize current status and advances in research on diagnosis and treatments of URSA, especially treatments such as LIT, IVIG, immunosuppressant, granulocyte colony-stimulating factor (G-CSF), intralipid, progesterone, anticoagulant, vitamin D, herbal medicine and preimplantation genetic testing for aneuploidies (PGT-A), aiming to provide a reference for doctors on choosing strategies for URSA patients.
What problem does this paper attempt to address?